Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Narcolepsy: full-pipeline trial registry

4 of 13 indexed Narcolepsy trials are currently recruiting.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 4 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Narcolepsy: 13 US clinical trials tracked, 4 recruiting.

Narcolepsy is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Jazz Pharmaceuticals, running 5 of these trials.

Enrollment posture brief

Registry condition narcolepsy

OPEN 4 | RECR 31% | LATE 3 | EARLY 3 | RANK #1315 | SPON 5

Nearest open-share peer: Acute Decompensated Heart Failure (31% recruiting · 13 trials)

ACL Injury61.5%Acute Biphenotypic Leukemia46.2%Narcolepsy (this)31%Accidental Falls30.8%Actinic Keratoses23.1%
Open-enrollment share among volume-matched conditions near Narcolepsy

Narcolepsy lists 4 open slots (31% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Narcolepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Narcolepsy is recruiting below its size-band peers.

    4 of 13 indexed trials (30.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Narcolepsy research.

    Jazz Pharmaceuticals accounts for 5 of 13 trials (38.5%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Narcolepsy enrolment sits around 140 participants.

    Median target enrolment is 140 among the 13 trials that report a genuine target (sentinel values excluded). 6 of those (46.2%) plan for fewer than 100 participants.

  4. Narcolepsy splits between interventional and observational designs.

    8 interventional and 5 observational studies make up this index (61.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 32Phase 41

Open and recent trials

13 total, page 1 of 1

RECRUITING 1,731 participants

SUNOSI® (Solriamfetol) Pregnancy Registry

Axsome Therapeutics

NCT06413420

RECRUITING 1,329 participants

WAKIX® (Pitolisant) Pregnancy Registry

Harmony Biosciences Management

NCT05536011

RECRUITING 500 participants

Child and Adolescent Registry for Participants With Narcolepsy

Jazz Pharmaceuticals

NCT04899947

RECRUITING Phase 1 8 participants

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

Jazz Pharmaceuticals

NCT06961266

COMPLETED Phase 3 247 participants

Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

Cephalon

NCT00228566

COMPLETED 212 participants

Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale

Boston Children's Hospital

NCT05373979

COMPLETED Phase 4 160 participants

A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

Jazz Pharmaceuticals

NCT05869773

COMPLETED Phase 3 140 participants

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Cephalon

NCT00107796

COMPLETED Phase 2 93 participants

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Jazz Pharmaceuticals

NCT01681121

COMPLETED 71 participants

Observational Study of LUMRYZ in Narcolepsy

Avadel

NCT06792708

COMPLETED NA 35 participants

Psychosocial Adjunctive Treatment for Hypersomnia (PATH)

Northwestern University

NCT03904238

COMPLETED Phase 2 33 participants

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Jazz Pharmaceuticals

NCT01485770

COMPLETED NA 7 participants

Narcolepsy Nightmare Study

Northwestern University

NCT05709873

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Narcolepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

ADX-N05 Drug
2 trials
Placebo Drug
2 trials
LUMRYZ Drug
1 trials
JZP258 Drug
1 trials
Cognitive-Behavior Therapy for Hypersomnia (CBT-H) Behavioral
1 trials
Targeted dream control Behavioral
1 trials
Imagery rehearsal therapy Behavioral
1 trials
Armodafinil Drug
1 trials

US sites by state

Facility locations filed on Narcolepsy trials. A trial with sites in several states counts in each.

Florida 7 trials
Illinois 5 trials
Georgia 5 trials
California 5 trials
Arizona 5 trials
Ohio 4 trials
Maryland 4 trials
Massachusetts 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Narcolepsy page

13 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Narcolepsy condition card totals 13 registered trials; most-linked intervention ADX-N05; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.